FMA
RPRX

FNY Managed Accounts’s Repros Therapeutics Inc. RPRX Stock Holding History

FNY Managed Accounts’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-14,000
Closed -$139K – 355
2014
Q3 		$139K Buy
+14,000
New +$207K 0.42% 52

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FNY Managed Accounts's RPRX Position: Q4 2014 in Review

FNY Managed Accounts sold out of Repros Therapeutics Inc. (RPRX) in Q4 2014, closing a stake of 14,000 shares — an estimated $139K sold.

FNY Managed Accounts first reported a position in RPRX in Q3 2014 and held it in 1 quarter. The position peaked at $139K in Q3 2014. 80 funds tracked by Wall St. Rank hold RPRX as of Q4 2014.

  • FNY Managed Accounts reported no remaining Repros Therapeutics Inc. position as of Q4 2014 after selling out during the quarter.
  • FNY Managed Accounts sold 14,000 Repros Therapeutics Inc. shares in Q4 2014, an estimated $139K.
  • FNY Managed Accounts first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 1 quarter.
  • FNY Managed Accounts's Repros Therapeutics Inc. position peaked at $139K in Q3 2014.
  • 80 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2014.

Based on FNY Managed Accounts's 13F filing for Q4 2014, filed 9 Jan 2015.